Evaluation of trough-based vancomycin therapy in achieving targeted area under the curve in haemodialysis cases.

  • Fazlollah Keshavarzi Faculty of Pharmaceutical Sciences, UCSI University
  • Vithyah Nadaraja Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia
  • Aliza Alias Pharmacy Division, Hospital Tengku Ampuan Rahimah Klang
  • Muhammad Junaid Farrukh Faculty of Pharmaceutical Sciences, UCSI University
  • Chuan Sheng Yap Faculty of Pharmaceutical Sciences, UCSI University
Keywords: Vancomycin, Haemodialysis, Trough concentration, Dosage adjustment, Bayesian pharmacokinetics

Abstract

Background & Objectives: Recently published IDSA guidelines on vancomycin dosing no longer advocates the use of trough concentrations as surrogate markers for clinical efficacy.  Protocols developed prior to revised targets may not reflect to the true efficacy marker for vancomycin that is AUC/MIC 400-600. This study aimed to evaluate the local vancomycin dosing protocol in achieving the target trough concentration and extrapolated AUC/MIC of 400-600 in patients with haemodialysis.

Methods: A retrospective analysis of therapeutic drug monitoring forms and individual medical records of haemodialysis patients was conducted. Vancomycin AUC of each individual was extrapolated via the use of a pharmacokinetic modelling software, PrecisePK®. Chi-square test of independence was used to determine the association of factors affecting AUC/MIC. A p value of 0.05 was considered statistically significant.

Results: A total number of 80 haemodialysis-dependent cases who were on vancomycin were recruited. More than 62% of haemodialysis patients showed AUC/MIC > 800. AUC/MIC was heavily influenced by minimum inhibitory concentration of the infecting microorganism. Interpretation & Conclusions: Exclusive trough-guided dosing may not translate well in achieving clinical efficacy of vancomycin in haemodialysis patients. Other contributing factors, especially MIC should be factored, as small MIC values account for greater reciprocal AUC/MIC values that increase the risk of loss of residual kidney function; a factor which is associated with overall mortality of HD patients.

Author Biographies

Fazlollah Keshavarzi, Faculty of Pharmaceutical Sciences, UCSI University

Assistant Professor, Clinical Pharmacist

Vithyah Nadaraja, Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia

Master of Clinical Pharmacy

Aliza Alias, Pharmacy Division, Hospital Tengku Ampuan Rahimah Klang

PhD, Clinical Pharmacy

Muhammad Junaid Farrukh, Faculty of Pharmaceutical Sciences, UCSI University

PhD, Assistant Professor of Clinical Professor

Chuan Sheng Yap, Faculty of Pharmaceutical Sciences, UCSI University

Lecturer, Master of Clinical Pharmacy 

References

Al-Talib, H. I., Yean, C. Y., Al-Jashamy, K., & Hasan, H. (2010). Methicillin-resistant Staphylococcus aureus nosocomial infection trends in Hospital Universiti Sains Malaysia during 2002-2007. Ann Saudi Med, 30(5), 358-363. https://doi.org/10.4103/0256-4947.67077
Avent, M. L., & Rogers, B. A. (2019). Optimising antimicrobial therapy through the use of Bayesian dosing programs. Int J Clin Pharm, 41(5), 1121-1130. https://doi.org/10.1007/s11096-019-00886-4
Barth, R. H., & DeVincenzo, N. (1996). Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int, 50(3), 929-936. https://doi.org/10.1038/ki.1996.393
Eleftheriadis, T., Liakopoulos, V., Leivaditis, K., Antoniadi, G., & Stefanidis, I. (2011). Infections in hemodialysis: a concise review - Part 1: bacteremia and respiratory infections. Hippokratia, 15(1), 12-17.
Finch, N. A., Zasowski, E. J., Murray, K. P., Mynatt, R. P., Zhao, J. J., Yost, R., . . . Rybak, M. J. (2017). A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrobial agents and chemotherapy, 61(12).
Krediet, R. T. (2017). Preservation of Residual Kidney Function and Urine Volume in Patients on Dialysis. Clinical Journal of the American Society of Nephrology, 12(3), 377. https://doi.org/10.2215/CJN.00330117
Launay-Vacher, V., Izzedine, H., Mercadal, L., & Deray, G. (2002). Clinical review: use of vancomycin in haemodialysis patients. Critical care (London, England), 6(4), 313-316. https://doi.org/10.1186/cc1516
Li, T., Wilcox, C. S., Lipkowitz, M. S., Gordon-Cappitelli, J., & Dragoi, S. (2019). Rationale and strategies for preserving residual kidney function in dialysis patients. American journal of nephrology, 50(6), 411-421.
McCoy, I. E., Shieh, L., & Fatehi, P. (2020). Reducing Phlebotomy in Hemodialysis Patients: A Quality Improvement Study. Kidney Med, 2(4), 432-436. https://doi.org/10.1016/j.xkme.2020.05.006
Musonda, P. Calculate Sample Size Needed to Test Relative Incidence in Self Controlled Case Series Studies: SCCS, Alt-2. HyLown Consulting LLC. Retrieved 9 April from http://powerandsamplesize.com/Calculators/Test-Relative-Incidence-in-Self-Controlled-Case-Series-Studies/SCCS-Alt-2
Neely, M. N., Kato, L., Youn, G., Kraler, L., Bayard, D., van Guilder, M., . . . Minejima, E. (2018). Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrobial agents chemotherapy, 62(2).
Pai, A. B., & Pai, M. P. (2004). Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm, 61(17), 1812-1816. https://doi.org/10.1093/ajhp/61.17.1812
Pai, M. P., Russo, A., Novelli, A., Venditti, M., & Falcone, M. (2014). Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example. Antimicrob Agents Chemother, 58(6), 3162-3167. https://doi.org/10.1128/AAC.02355-14
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., . . . Rotschafer, J. C. (2020). Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy.
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., . . . Lomaestro, B. M. (2020). Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm, 77(11), 835-864. https://doi.org/10.1093/ajhp/zxaa036
Surendra, N. K., Rizal, A. M., Hooi, L. S., Bavanandan, S., Mohamad Nor, F. S., Shah Firdaus Khan, S., & Ong, L. M. (2018). The cost of dialysis in Malaysia: hemodialysis and continuous ambulatory peritoneal dialysis. Malaysian Journal of Public Health Medicine, 18(Suppl 2), 70-81.
Turner, R. B., Kojiro, K., Shephard, E. A., Won, R., Chang, E., Chan, D., & Elbarbry, F. (2018). Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients. Pharmacotherapy, 38(12), 1174-1183. https://doi.org/10.1002/phar.2191
Yeoh, L. Y., Tan, F. L., Willis, G. C., & Ooi, S. T. (2014). Methicillin-resistant Staphylococcus aureus carriage in hospitalized chronic hemodialysis patients and its predisposing factors. Hemodial Int, 18(1), 142-147. https://doi.org/10.1111/hdi.12061
Zasowski, E. J., Murray, K. P., Trinh, T. D., Finch, N. A., Pogue, J. M., Mynatt, R. P., & Rybak, M. J. (2017). Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. Antimicrob Agents Chemother, 62(1), e01684-01617. https://doi.org/10.1128/AAC.01684-17
Published
2022-09-28
How to Cite
Keshavarzi, F., Nadaraja, V., Alias, A., Farrukh, M. J., & Yap, C. S. (2022). Evaluation of trough-based vancomycin therapy in achieving targeted area under the curve in haemodialysis cases. Indonesian Journal of Pharmacy, 33(3), 484-492. https://doi.org/10.22146/ijp.4433
Section
Research Article